



EAPCI
European Association of
Percutaneous Cardiovascular
Interventions



ESC
European Society
of Cardiology

European Association of Percutaneous Cardiovascular Interventions

FLAVIO LUCIANO RIBICHINI
ITALY

**Application for the following position in the EAPCI Board:
SECRETARY**

Current position

- Full Professor of Cardiovascular Medicine, University of Verona, Italy
- Director School of Cardiovascular Medicine, University of Verona, Italy
- Director Cardiovascular Division, Verona University Hospitals
- Chairman Cardio-Thoracic Department, Verona University Hospitals

Profession

- Interventionalist
- Healthcare Professional (Nurse, Radiographer, Technician) working in PCI
- Industry Professional
- Other

Additional Information

- EAPCI Member
- Active in an ESC Member Country
If yes, specify your country of work: Italy
- Member of a National Cardiac Society
*If yes, specify: Italian Society of Cardiology (**SIC**), Italian Federation of Cardiology (**FIC**), Italian Society of Interventional Cardiology – (**GISE**)*
- Member of an Interventional Working Group
If yes, specify: Working Group on Interventional Cardiology of the Italian Society of Cardiology (SIC)

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

General CV (as it pertains to PCI) – 300 words max

2021-at present	Director of the International Master in Interventional Cardiology, University of Verona
2019-at present	Faculty of PCR-EDU online Webinars
2022-at present	Chairman of the Research and Fellowship Committee of the European Association of Percutaneous Cardiac Interventions 2022-2024
2018-at present	Member of the Board of Directors of the European Association of Percutaneous Cardiac Interventions (EAPCI) 2018-2020, 2020-2022, 2022-2024.
2017-at present	Full Professor of Cardiovascular Medicine, University of Verona, Italy Director School of Cardiovascular Medicine, University of Verona, Italy Director Cardiovascular Division, Verona University Hospitals Chairman Cardio-Thoracic Department, Verona University Hospitals
2014-2017	Director of the PhD School Life and Health of the University of Verona
2010-at present	Member of the program committee and Scientific Board of PCR
2008-at present	Member of the Editorial Board of the European Heart Journal
2006-2017	Associate Professor of the University of Verona, Italy, and Director of the Catheterization Laboratories of the University Hospitals (AOUI di Verona)
2002-2005	Assistant Professor of the Universidad del Piemonte Orientale, Novara, Italy, and Director of the Catheterization Laboratory of the Ospedale Maggiore della Carità di Novara.
1992-2002	Staff member of the Interventional Cardiology, Division of Cardiology, Ospedale Santa Croce di Cuneo, Italy
1993-2000	Training periods in interventional cardiology at Hospital Henry Mondor, University of Paris, Stanford University Palo Alto, US, Mount Sinai Hospital, New York, US, OLV Cardiovascular Center, Aalst, Belgium as ESC Research Fellow, and the Armed Force Institute of Pathology Washington, US.
1992	Board certification in Cardiology, University of Turin, Italy
1989	Board certification of Medicine, University of Turin, Italy
1987-98	Two-year Residence Internship in Internal Medicine, Hospital Privado de Cordoba, Argentina
1986	Board certification of Medicine, University of Cordoba, Argentina

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Previous experience in EAPCI, ESC or your National Bodies

1998 – 1999: Member of the Scientific Committee of the Italian Society of Interventional Cardiology (GISE)

For previous experiences in EAPCI see below

If you have been involved in EAPCI in the past, please specify the position(s) as well as the relevant date(s)

In particular, please indicate if you served in:

- | | | |
|---|------------|-----------|
| • EAPCI Board 2022-2024 (under E. Barbato's leadership)? | Yes | No |
| • EAPCI Board 2020-2022 (under D. Dudek's leadership)? | Yes | No |
| • EAPCI Board 2018-2020 (under A. Baumbach's leadership)? | Yes | No |
| • EAPCI Board 2016-2018 (under M. Haude's leadership)? | Yes | No |

If you answered yes to at least one of these questions, please provide details.

- Under E. Barbato's leadership (2022-at present), I've served as EAPCI member of the Board as Chair of the Grants and Fellowship Committee.
- Under D. Dudek's leadership (2020-2022) I've served as EAPCI member of the Board of Directors as PCR Representative.
- Under A. Baumbach's leadership (2018-2020), I've served as EAPCI member of the Board of Directors as PCR Representative.

Publications in the field of PCI (most important 10 publications)

1. Weaver D, Simes J, Betriu A, Grines C, Zijlstra F, Garcia E, Grinfeld L, Gibbons R, Ribeiro E, DeWood M, **Ribichini F**.

Primary coronary angioplasty vs. intravenous thrombolysis for treatment of acute myocardial infarction: A quantitative overview of their comparative effectiveness.

JAMA 1997; 278: 2093-2098. PMID: 9403425

2. **Ribichini F**, Steffenino G, Dellavalle A, Ferrero V, Vado A, Feola M, Uslenghi E.

Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized trial.

J Am Coll Cardiol 1998; 32:1687-1694. PMID: 9822097

3. Ferrero V, **Ribichini F**, Matullo G, Guarrera S, Carturan S, Vado A, Vassanelli C, Piazza A, Uslenghi E, Wijns W. Estrogen receptor- α polymorphisms and angiographic outcome after coronary artery stenting.

Arterioscler Thromb Vasc Biol 2003;23:2223-2228. PMID: 14563649

4. **Ribichini F**, Pugno F, Ferrero V, Bussolati G, Feola M, Russo P, Di Mario C, Colombo A, Vassanelli C.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Cellular immunostaining of angiotensin-converting enzyme in human coronary atherosclerotic plaques.

J Am Coll Cardiol 2006;47:1143-9. PMID: 16545643. DOI: [10.1016/j.jacc.2005.12.022](https://doi.org/10.1016/j.jacc.2005.12.022)

5. Ribichini F, Joner M, Ferrero V, Finn AV, Crimins J, Nakazawa G, Acampado E, Kolodgie FD, Virmani R.

Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis.

J Am Coll Cardiol. 2007 Jul 10;50(2):176-85. Epub 2007 Jun 22. PMID: 17616304. DOI: [10.1016/j.jacc.2007.03.031](https://doi.org/10.1016/j.jacc.2007.03.031)

6. Tomai F, Pesarini G, Castriota F, Reimers B, De Luca L, De Persio G, Spartà D, Aurigemma C, Cremonesi A, Ribichini F;

Finalized Research in Endovascular Strategies Study Group. Early and long-term outcomes after combined percutaneous revascularization in patients with carotid and coronary artery stenoses.

JACC Cardiovasc Interv. 2011 May;4(5):560-8. doi: [10.1016/j.jcin.2011.01.012](https://doi.org/10.1016/j.jcin.2011.01.012).

7. Ribichini F, Tomai F, Pesarini G, Zivelonghi C, Rognoni A, De Luca G, Boccuzzi G, Presbitero P, Ferrero V, Ghini AS, Marino P, Vassanelli C; CEREAS-DES Investigators.

Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES versus BMS alone to Eliminate Restenosis (CEREAS-DES).

Eur Heart J. 2013 Jun;34(23):1740-8. doi: [10.1093/eurheartj/ehs079](https://doi.org/10.1093/eurheartj/ehs079). Epub 2013 Mar 14.

8. Pesarini G, Scarsini R, Zivelonghi C, Piccoli A, Gambaro A, Gottin L, Rossi A, Ferrero V, Vassanelli C, Ribichini F.

Functional Assessment of Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Implantation: Influence of Pressure Overload on the Evaluation of Lesions Severity.

Circ Cardiovasc Interv. 2016 Nov;9(11). pii: e004088. PMID:27803040. DOI: [10.1161/CIRCINTERVENTIONS.116.004088](https://doi.org/10.1161/CIRCINTERVENTIONS.116.004088)

9. Intravascular ultrasound assessment of coronary ostia following valve-in-valve transcatheter aortic valve implantation.

Pighi M, Lunardi M, Pesarini G, Castriota F, Venturi G, Gottin L, Scarsini R, Ferrero V, **Ribichini FL.**

EuroIntervention. 2021 Feb 19;16(14):1148-1151. doi: [10.4244/EIJ-D-20-00611](https://doi.org/10.4244/EIJ-D-20-00611). PMID: 32894228

10. Management strategies for heavily calcified coronary stenoses: an EAPCI clinical consensus statement in collaboration with the EURO4C-PCR group.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

Barbato E, Gallinoro E, Abdel-Wahab M, Andreini D, Carrié D, Di Mario C, Dudek D, Escaned J, Fajadet J, Guagliumi G, Hill J, McEntegart M, Mashayekhi K, Mezilis N, Onuma Y, Reczuch K, Shlofmitz R, Stefanini G, Tarantini G, Toth GG, Vaquerizo B, Wijns W, **Ribichini FL**.

Eur Heart J. 2023 Nov 1;44(41):4340-4356. doi: 10.1093/eurheartj/ehad342

What would you like to achieve if you were elected?

Given the 2-years mandate, beyond the secretarial tasks inherent to the elected position, I would like to focus my activity within the board on 3 main objectives:

- **Better and equal recognition of the primary PCI commitment throughout the EU.** Performing 24/24h primary PCI is the most important mission of interventional teams worldwide. This is, with no doubts, the most life-saving intervention an interventionalist can perform. Following the example of the pioneers who created the Stent for Life initiative, I would like to continue the work in this field with special focus on two objectives: enlarging the STEMI networks in developing countries and promoting a European campaign aimed at valorizing the recognition of this demanding professional endeavor. Indeed, there is still great disparity in the access to care worldwide as well as on the economic retribution to doctors and NAPS performing primary PCI between European Countries and I think that EAPCI should work on both aspects, the further availability of primary PCI as a life-saving care, and the acknowledgement that this important task deserves.
- **EAPCI educational opportunities:** Considering the substantial impulse that EAPCI and its associates have derived from my work as Chair of the Fellowship Grant Committee, I would like to continue cooperating with the EAPCI Board to further enlarge the possibilities of studying, training, and working on research projects for young cardiologist, by consolidating a standardized method for found-rising and engagement of training centers. In particular, obtaining a further increment of the number of grants, securing gender equity and helping candidates from Countries with limited opportunities as it has been done during my period as chairman of the Fellowship and Grants committee.
- **Closer integration of the National Societies and EAPCI:** Reinforcing the presence and participation of the National Societies is a necessary step to consolidate the Association and to achieve its objectives, being those ongoing, like the European Certification of Interventional Cardiology, and those to come, as those proposed above (expansion and recognition of the stent for life program performed by PCI teams throughout the EU and out of EU). To encourage a larger participation of cardiologists all around Europe and neighbor Countries I would like to propose to include in EAPCI other Countries that yet do not belong to the ESC Universe and to consider a differentiated membership rate according to the candidates position and the Country economic situation, in particular those with lower incomes, and also for fellows and NAPS, not only for specialists younger than 40.

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.

If you were elected, how do you envisage to organize yourself to accommodate this very demanding additional commitment?

I have been nominated Head of the Division of Cardiology and Director of the School of Cardiovascular Medicine at the University of Verona 7 years ago. This time has been enough to organize my clinical and directional activities. Furthermore, since the last two years I am also the Chairman of the Cardio-Thoracic Department, that includes the direction of the Divisions of Cardiac Surgery, Thoracic Surgery, Vascular Surgery, Pneumology, Angiology and Cystic Fibrosis. Such position has exposed me to further experience and networking that can help me in managing the demanding EAPCI-related tasks and duties.

In the last 6 years, I've been member of the EAPCI board as Chair of the Fellowship Grants Committee and as a PCR representative, therefore learning and working in tight contact with the people and the organization of the Association and sharing its vision and mission. I am confident that through a close collaboration with the President and with the other EAPCI board members I may contribute to the success of the Board accommodating this demanding additional commitment to my working timetable.

Recommendation letter(s)

Personal Data Privacy

The information collected is subject to computerised processes to make a list of candidates to the elections to be reviewed by the EAPCI Nominating Committee 2024-2026 from among those indicating an interest in EAPCI elected positions.

The recipients of the data are:

- *The internal staff following the elections*
- *EAPCI Nominating Committee 2*
- *EAPCI Voting members, during the e-voting*
- *Visitors EAPCI/ESC Websites*
- *National Cardiac Societies and Interventional Working Groups*

All data are mandatory.

Other data requested enables us to contact you if any further information is required during the election process.

In accordance with the law N°78-17 of January 6, 1978, amended in 2004, relating to the protection of individuals with regard to the processing of personal data, you have a right to access and rectify information concerning you, which you can exercise by contacting (together with proof of identity):

To reduce the burden of cardiovascular disease through Percutaneous Cardiovascular Interventions.